白癜风患者CLEC-2BmRNA表达及其与临床相关性研究
发布时间：2019-04-26 18:28
【摘要】：目的 探讨CLEC-2B (C-type lectin domain family 2, member B)基因在白癜风患者外周血与皮损中的表达与疾病临床类型、病程、病期、转归的相关性,并进行皮损区CLEC-2B基因的蛋白表达,以明确CLEC-2B基因表达的细胞定位。通过本实验发现疾病多样性及临床转归与基因差异表达的相关性,据此预测白癜风发生、临床分型、分期及预后,从而对临床起到一定的指导作用。 方法 应用反转录-聚合酶链式反应(reverse transcription-polymerase chain reaction, RT-PCR)方法,对白癜风患者及正常对照者外周血及皮肤组织中CLEC-2B的表达量进行分析,扩增产物经4.0%琼脂糖溴乙锭电泳,凝胶成像仪下摄像证实。按照白癜风的诊断标准,利用统计软件分析不同临床类型、不同病期、不同病程、不同转归的白癜风皮损区、外周血及正常人皮肤、外周血CLEC-2B基因表达的差异。并对白癜风患者皮损组织与正常皮肤组织,用免疫组织化学方法确定皮肤组织中CLEC-2B基因的蛋白表达。 结果 1.白癜风患者组皮损中CLEC-2BmRNA表达量高于正常对照组,差异有统计学意义(t=2.581,P0.05)。 2.白癜风患者与正常对照组外周血中CLEC-2BmRNA的表达量比较差异无统计学意义(t=1.375,P0.05)。 3.不同性别白癜风患者皮损组中CLEC-2BmRNA表达量比较无统计学差异(t=1.341,P0.05)。 4.不同病程白癜风患者皮损中CLEC-2BmRNA的表达量比较差异无统计学意义(F=1.479,P0.05)。 5.寻常型白癜风皮损组中CLEC-2BmRNA的表达量高于节段型白癜风组,差异有统计学意义(t=2.432,P0.05)。 6.进展期白癜风患者组皮损中CLEC-2BmRNA的表达量高于稳定期患者组,差异有统计学意义(t=2.204,P0.05)。 7.在不同转归的白癜风患者中,各组皮损中CLEC-2B mRNA的表达量差别有统计学意义(F=5.218,P0.05)。 8.通过免疫组织化学方法证实在白癜风皮损真皮层中的淋巴细胞中有CLEC-2B蛋白的表达。 结论 1.白癜风患者皮损中CLEC-2B的表达水平的增高,提示CLEC-2B在白癜风发病机制中具有一定的意义。 2.白癜风患者进展期CLEC-2B的表达水平高于稳定期患者,提示CLEC-2B与白癜风病期进展有关。 3. CLEC-2B在寻常型白癜风的表达水平高于节段型白癜风,提示CLEC-2B在决定白癜风的分型中起一定的作用,同时推测CLEC-2B可能参与白癜风的免疫机制。 4.不同转归的白癜风患者CLEC-2B的表达水平差异有统计学意义,从而在基因水平揭示同一疾病不同转归的谜底,指导临床诊断和预后。同时为寻找调控该基因的药物,改善疾病转归奠定基础。 5. CLEC-2B蛋白表达于白癜风患者皮损真皮层淋巴细胞的细胞核中,进一步加深了对本基因的认识。
[Abstract]:Objective to investigate the expression of CLEC-2B (C-type lectin domain family-2, member B) gene in peripheral blood and lesions of patients with vitiligo and its correlation with clinical type, course of disease, stage of disease and prognosis. The protein expression of CLEC-2B gene was carried out to identify the cellular localization of CLEC-2B gene expression. In this study, we found the correlation between disease diversity and clinical outcome and gene differential expression, so as to predict the occurrence, clinical classification, staging and prognosis of vitiligo, and thus play a guiding role in clinical practice. Methods reverse transcription polymerase chain reaction (reverse transcription-polymerase chain reaction, RT-PCR) was used to analyze the expression of CLEC-2B in peripheral blood and skin of patients with vitiligo and normal controls. The amplified products were confirmed by 4.0% agarose bromide ethidium electrophoresis. According to the diagnostic criteria of vitiligo, statistical software was used to analyze the difference of CLEC-2B gene expression in different clinical types, different disease stages, different course of disease, different prognosis of vitiligo skin, peripheral blood and normal skin, and peripheral blood. The protein expression of CLEC-2B gene in the skin tissue of patients with vitiligo and normal skin tissue was determined by immunohistochemical method. Outcome 1. The expression of CLEC-2BmRNA in the lesions of patients with vitiligo was significantly higher than that of normal controls (t = 2.581, P0.05). 2. There was no significant difference in the expression of CLEC-2BmRNA in peripheral blood between vitiligo patients and normal controls (t = 1.375, P0.05). 3. There was no significant difference in the expression of CLEC-2BmRNA between male and female patients with vitiligo (t = 1.341, P0.05). 4. There was no significant difference in the expression of CLEC-2BmRNA in the lesions of patients with vitiligo at different stages (F = 1.479, P0.05). 5. The expression of CLEC-2BmRNA in vitiligo vulgaris group was higher than that in segmental vitiligo group (t = 2.432, P0.05). 6. The expression of CLEC-2BmRNA in skin lesions of patients with progressive vitiligo was significantly higher than that of patients with stable vitiligo (t = 2.204, P0.05). 7. In the patients with vitiligo with different outcomes, the expression of CLEC-2B mRNA in the lesions of each group was significantly different (F = 5.218, P0.05). 8. The expression of CLEC-2B protein was confirmed by immunohistochemical method in the lymphocytes of the dermis of vitiligo. Conclusion 1. The increased expression of CLEC-2B in the lesions of patients with vitiligo suggests that CLEC-2B may play an important role in the pathogenesis of vitiligo. 2. The expression level of CLEC-2B in patients with advanced vitiligo was higher than that in patients with stable vitiligo, suggesting that CLEC-2B was related to the progression of vitiligo. 3. The expression level of CLEC-2B in vitiligo vulgaris is higher than that in segmental vitiligo, suggesting that CLEC-2B may play a role in determining the classification of vitiligo, and that CLEC-2B may be involved in the immune mechanism of vitiligo. 4. The expression level of CLEC-2B in vitiligo patients with different prognosis has statistical significance, so as to reveal the mystery of different outcomes of the same disease at the gene level, and guide the clinical diagnosis and prognosis. At the same time, it lays a foundation for finding the drugs that regulate the gene and improving the prognosis of the disease. 5. The expression of CLEC-2B protein in the nuclei of dermis lymphocytes from patients with vitiligo further enhanced the understanding of this gene.
【学位授予单位】：天津医科大学
【学位级别】：硕士
【学位授予年份】：2011
【分类号】：R758.41
本文编号：2466293
[Abstract]:Objective to investigate the expression of CLEC-2B (C-type lectin domain family-2, member B) gene in peripheral blood and lesions of patients with vitiligo and its correlation with clinical type, course of disease, stage of disease and prognosis. The protein expression of CLEC-2B gene was carried out to identify the cellular localization of CLEC-2B gene expression. In this study, we found the correlation between disease diversity and clinical outcome and gene differential expression, so as to predict the occurrence, clinical classification, staging and prognosis of vitiligo, and thus play a guiding role in clinical practice. Methods reverse transcription polymerase chain reaction (reverse transcription-polymerase chain reaction, RT-PCR) was used to analyze the expression of CLEC-2B in peripheral blood and skin of patients with vitiligo and normal controls. The amplified products were confirmed by 4.0% agarose bromide ethidium electrophoresis. According to the diagnostic criteria of vitiligo, statistical software was used to analyze the difference of CLEC-2B gene expression in different clinical types, different disease stages, different course of disease, different prognosis of vitiligo skin, peripheral blood and normal skin, and peripheral blood. The protein expression of CLEC-2B gene in the skin tissue of patients with vitiligo and normal skin tissue was determined by immunohistochemical method. Outcome 1. The expression of CLEC-2BmRNA in the lesions of patients with vitiligo was significantly higher than that of normal controls (t = 2.581, P0.05). 2. There was no significant difference in the expression of CLEC-2BmRNA in peripheral blood between vitiligo patients and normal controls (t = 1.375, P0.05). 3. There was no significant difference in the expression of CLEC-2BmRNA between male and female patients with vitiligo (t = 1.341, P0.05). 4. There was no significant difference in the expression of CLEC-2BmRNA in the lesions of patients with vitiligo at different stages (F = 1.479, P0.05). 5. The expression of CLEC-2BmRNA in vitiligo vulgaris group was higher than that in segmental vitiligo group (t = 2.432, P0.05). 6. The expression of CLEC-2BmRNA in skin lesions of patients with progressive vitiligo was significantly higher than that of patients with stable vitiligo (t = 2.204, P0.05). 7. In the patients with vitiligo with different outcomes, the expression of CLEC-2B mRNA in the lesions of each group was significantly different (F = 5.218, P0.05). 8. The expression of CLEC-2B protein was confirmed by immunohistochemical method in the lymphocytes of the dermis of vitiligo. Conclusion 1. The increased expression of CLEC-2B in the lesions of patients with vitiligo suggests that CLEC-2B may play an important role in the pathogenesis of vitiligo. 2. The expression level of CLEC-2B in patients with advanced vitiligo was higher than that in patients with stable vitiligo, suggesting that CLEC-2B was related to the progression of vitiligo. 3. The expression level of CLEC-2B in vitiligo vulgaris is higher than that in segmental vitiligo, suggesting that CLEC-2B may play a role in determining the classification of vitiligo, and that CLEC-2B may be involved in the immune mechanism of vitiligo. 4. The expression level of CLEC-2B in vitiligo patients with different prognosis has statistical significance, so as to reveal the mystery of different outcomes of the same disease at the gene level, and guide the clinical diagnosis and prognosis. At the same time, it lays a foundation for finding the drugs that regulate the gene and improving the prognosis of the disease. 5. The expression of CLEC-2B protein in the nuclei of dermis lymphocytes from patients with vitiligo further enhanced the understanding of this gene.
【学位授予单位】：天津医科大学
【学位级别】：硕士
【学位授予年份】：2011
【分类号】：R758.41
【参考文献】
相关期刊论文 前10条
1 张启国;方春红;曾静;罗芳;徐世正;姚莹;张璃;;寻常型进展期白癜风患者外周血T淋巴细胞Fas和FasL的表达[J];临床皮肤科杂志;2006年03期
2 李凯;高琳;杨励;齐显龙;李春英;高天文;;COMT基因单核苷酸多态性与汉族白癜风发病的相关性[J];中国美容医学;2007年03期
3 王梁燕,洪奇华,张耀洲;实时定量PCR技术及其应用[J];细胞生物学杂志;2004年01期
4 王丹妮;权晟;袁锋;张麟;左先波;孙良丹;杨森;张学军;;COMT基因遗传多态性与汉族人白癜风易感性关联分析[J];安徽医科大学学报;2009年03期
5 张麟;袁锋;王丹妮;王培光;孙良丹;张学军;杨森;;CTLA4基因多态性与汉族人白癜风易感性相关分析[J];安徽医科大学学报;2009年03期
6 袁锋;权晟;王丹妮;张麟;左先波;孙良丹;杨森;张学军;;PTPN22基因多态性与汉族人白癜风易感性关联分析[J];安徽医科大学学报;2009年03期
7 王岩,肖毅,张晓东,赵玉铭,刘永学,宋芳吉,陈洪铎;有无家族史白癜风与HLA-Ⅰ类抗原的关联性研究[J];中国皮肤性病学杂志;2001年03期
8 肖毅,赵玉铭,宋芳吉,刘永学,高德凯,杨克力;HLA-DRB1等位基因与中国北方汉族 白癜风的相关性[J];中华皮肤科杂志;2000年01期
9 李志强,刘荣卿,高天文,赵小东,陈金穆;白癜风患者血清中抗黑素细胞膜表面抗原自身抗体的检测[J];中华皮肤科杂志;2001年04期
10 程东庆,许爱娥,刘红焱,鲍建芳,沈建根,邵传森;白癜风患者外周血T淋巴细胞、自然杀伤细胞功能的研究[J];中华皮肤科杂志;2001年06期
相关硕士学位论文 前1条
1 唐果;CTLA-4基因单核苷酸多态性与白癜风相关性研究[D];第四军医大学;2007年
，本文编号：2466293
本文链接：https://www.wllwen.com/yixuelunwen/pifb/2466293.html
最近更新
教材专著
